Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 2/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | SMPD3 | Q9NY59 | 4/20 | 0.42 |
| ▸ | WHR1 | P49842 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4077902 | 0.76 | CA12 (0.46) | TDO2IDO1KMT2AALDH1A1LMNA | |
| SCHEMBL4077907 | 0.74 | CA12 (0.40) | TDO2IDO1KMT2AALDH1A1LMNA | |
| SCHEMBL6777206 | 0.71 | NPC1 (0.55) | TDO2IDO1HSP90AA1CTDSP1ALDH1A1 | |
| SCHEMBL6779688 | 0.71 | ALDH1A1 (0.46) | TDO2IDO1KMT2ASMPD3WHR1 | |
| SCHEMBL13313198 | 0.70 | ADORA2A (0.51) | WHR1ALDH1A1LMNAKDM4EGAA | |
| Hydrochloric Acid SCHEMBL6542516 | 0.69 | TDO2 (0.53) | TDO2IDO1KMT2ASMPD3ALDH1A1 | |
| SCHEMBL10613423 | 0.68 | GRM5 (0.44) | TDO2IDO1KMT2AALDH1A1LMNA | |
| SCHEMBL30081970 | 0.68 | TDO2 (0.69) | TDO2IDO1ALDH1A1LMNAGAA | |
| SCHEMBL16098147 | 0.67 | CTDSP1 (0.51) | TDO2IDO1CTDSP1KMT2AWHR1 | |
| SCHEMBL12851816 | 0.67 | MAPT (0.48) | KMT2AALDH1A1LMNAKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6723736-B2 | FOR THERAPY INFLAMMATION, INFLAMMATORY DISEASES, IMMUNOLOGIC DISEASES AND OTHER DISEASES MEDIATED BY TUMOR NECROSIS FACTOR-ALPHA (TNF-ALPHA) AND/OR INTERLEUKIN 6 OR 10 AND/OR ENZYME CYCLOOXYGENASE-2 (COX-2) | THERACOS, INC. | 2004-04-20 | — | — | US | claimed |
| US-20020077333-A1 | Tricyclic compounds and uses thereof | THERACOS, INC. | 2002-06-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077333-A1 | Tricyclic compounds and uses thereof | IL6, TNF, IL2 | TDO2 1098/4885IDO1 66/4885HSP90AA1 550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.